Activbiotics, Inc.

Merck Sharp + Dohme Corp.

Cardax Pharmaceuticals, Inc.

Activbiotics Pharma, LLC

University of Michigan

Astrazeneca Ab

Albany Molecular Research, Inc.

Bone Care International, Inc.

William Bert Geiss

Arthur F Michaelis

John Henry Van Duzer

Douglas Gregory Stafford

Xiang Y Yu

Joseph Raker

James Michael Siedlecki

Yingfei Yang

Andrew William Stamford

Peng Cho Tang

Michael W Miller

Scott D Edmondson

Henry Lee Jackson

Samuel Fournier Lockwood

Geoff Nadolski

Richard Williams

Zhiqiang Guo

Brian Thomas Gregg

David C Burdick

Zhiqiang Fang

Van-Duc Le

Yishu Du

Min Yang

Ping Liu

Deen Tulshian

Duane E DeMong

Gregori J Morriello

Harold B Wood

Cheng Zhu

Bowei Wang

Milana M Maletic

Harold Meckler

Wanying Sun

Rajan Anand

Robert Jason Herr

Gregory Scott Martin

Sverker Von Unge

Liping Wang

Lehua Chang

Yuping Zhu

Joel M Harris

Vincent Colandrea

Julius J Matasi

Michael F Czarniecki

David John Fairfax

Kallol Basu

Nam Fung Kar

Zhiyong Hu

Hawkins V Maulding

Jason W Szewczyk

Kake Zhao

Anders Lehmann

Yong Huang

Gunnel E Sundén

Chalom B Sayada

Mark A Helle

Megan Macala

James C Haber, Jr

Stephanie Nicole Cooke

Manzer Durrani

Dmytro O Tymoshenko

Lisa Helen Peterson

Barry Eisenstein

Kevin Fitzpatrick

The present invention relates to methods and intermediates for the preparation of omacetaxine and cephalotaxine derivatives thereof. The resulting products are useful in the treatment of proliferative diseases and infectious diseases.

Methods and intermediates for the preparation of omacetaxine and cephalotaxine derivatives thereof

Substituted cyclopropyl compounds of the formula I and the pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. The compounds are useful as agonists of the g-protein coupled receptor GPR-119. Pharmaceutical compositions and methods of treatment are also included. Another aspect of the invention that is of interest relates to compounds of formula 1a. 

Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment

Substituted cyclopropyl compounds of the formula I: and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR-119. Pharmaceutical compositions and methods of treatment are also included. 

The present invention relates to Polycyclic Guanine Derivatives, compositions comprising the Polycyclic Guanine Derivatives and methods of using the Polycyclic Guanine Derivatives to treat pain or an inflammatory disease.

Polycyclic guanine derivatives and use thereof

The present invention relates to novel chemical compounds, methods for their discovery, and their therapeutic use. In particular, the present invention provides benzodiazepine derivatives and related compounds and methods of using benzodiazepine derivatives and related compounds as therapeutic agents to treat a number of conditions associated with the faulty regulation of the processes of programmed cell death, autoimmunity, inflammation, hyperproliferation, and the like.

Soluble 1,4 benzodiazepine compounds and stable salts thereof

The present invention features rifamycin analogs and methods of using these compounds to treat a variety of microbial infections.

Rifamycin analogs and uses thereof

The present invention features rifamycin analogs that can be used as therapeutics for treating or preventing a variety of microbial infections. In one form, the analogs are acetylated at the 25-position, as is rifamycin. In another form, the analogs are deacetylated at the 25-position. In yet other forms, benzoxazinorifamycin, benzthiazinorifamycin, and benzdiazinorifamycin analogs are derivatized at various positions of the benzene ring, including 3'-hydroxy analogs, and/or various fused ring systems with the benzene ring at the 4&#x2032;,5&#x2032; or 5&#x2032;,6&#x2032; positions.

A method for synthesizing intermediates for use in the synthesis of carotenoid synthetic intermediates, carotenoid analogs, and/or carotenoid derivatives. The carotenoid analog, derivative, or intermediate may be administered to a subject for the inhibition and/or amelioration of any disease that involves production of reactive oxygen species, reactive nitrogen species, radicals and/or non-radicals. In some embodiments, the invention may include methods for synthesizing chemical compounds including an analog or derivative of a carotenoid. Carotenoid analogs or derivatives may include acyclic end groups. In some embodiments, a carotenoid analog or derivative may include at least one substituent. The substituent may enhance the solubility of the carotenoid analog or derivative such that the carotenoid analog or derivative at least partially dissolves in water.

Methods for synthesis of carotenoids, including analogs, derivatives, and synthetic and biological intermediates

The present invention features rifamycin analogs that can be used as therapeutics for treating or preventing a variety of microbial infections. In one form, the analogs are acetylated at the 25-position, as is rifamycin. In another form, the analogs are deacetylated at the 25-position. In yet other forms, benzoxazinorifamycin, benzthiazinorifamycin, and benzdiazinorifamycin analogs are derivatized at various positions of the benzene ring, including 3'-hydroxy analogs, 4&#x2032;- and/or 6&#x2032; halo and/or alkoxy analogs, and various 5&#x2032; substituents that incorporate a cyclic amine moiety.

A method used for synthesizing intermediates for use in the synthesis of carotenoids and carotenoid analogs, and/or carotenoid derivatives. In some embodiments, the invention includes methods for synthesizing optically active intermediates useful for the synthesis of optically active carotenoids. Synthesis of optically active carotenoids, in one embodiment, may be accomplished by forming an optically active dihydroxy intermediate from ketoisopherone. The optically active dihydroxy intermediate may be converted into optically active astaxanthin derivatives.

Methods for the synthesis of astaxanthin

The invention features sulfhydryl rifamycin compositions, methods of making these compositions, and methods for treating disease using these compositions.

Sulfhydryl rifamycins and uses thereof

Novel compounds of formula (I) wherein Rrepresents hydrogen; Rrepresents hydroxy, fluoro, or an oxo group; Rrepresents hydrogen; Rrepresents hydrogen; and pharmaceutically acceptable salts, solvates, and the stereoisomers thereof, with the exception of the racemate of (3-amino-2-hydroxypropyl)sulphinic acid. The compounds are useful in therapy, especially for the treatment of reflux disease. The invention is also related to processes for their preparation, intermediates of said process and pharmaceutical compositions containing said therapeutically active compounds and to the use of said active compounds in therapy

Compounds useful in reflux disease

The invention provides a method for making 24(S)-hydroxyvitamin D which is a stereospecific synthesis.

Method for making 24(S)-hydroxyvitamin D2

Growing community of inventors

Athens, NY, United States of America

William Bert Geiss